Cancer Genetics' Focus::Lymphoma Panel

Cancer Genetics has launched Focus::Lymphoma, a CLIA-validated, next-generation sequencing panel to detect and monitor the most common mature B-cell lymphomas. The panel enables the targeted sequencing of 220 genes and has the ability to customize the reporting that provides clinically actionable information to determine patients' treatment options. The product can detect mutations in genes such as BTK and PLCG2, which have been recently attributed to therapy resistance, and offers information on genes such as MT2D, which is frequently mutated in B-cell lymphomas, but is not currently available through other commercial platforms.